MedTrace Logo

Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes

NCT00976495 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2017-03-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effects of dapagliflozin on kidney function, as assessed by glomerular filtration rate.

Conditions

Interventions

DRUG

Dapagliflozin

Tablets, Oral, 10 mg, once daily, 12 weeks

DRUG

Placebo

Tablets, Oral, 0 mg, once daily, 12 weeks

DRUG

Hydrochlorothiazide

Tablets, Oral, 25 mg, once daily, 12 weeks

Sponsors & Collaborators

  • Astra Zeneca, Bristol-Myers Squibb

    collaborator OTHER

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States
  • Canada
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00976495 on ClinicalTrials.gov